Screener
R&D at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenues: | ||
| License revenue | $463 | $1,163 |
| Operating expenses: | ||
| Research and development | 34,528 | 27,003 |
| General and administrative | 12,468 | 7,337 |
| Total operating expenses | 46,996 | 34,340 |
| Loss from operations | (46,533) | (33,177) |
| Other income/(expense): |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's R&D?
- Dianthus Therapeutics (DNTH) reported R&D of $34.53M in Q1 2026.
- How has Dianthus Therapeutics's R&D changed year-over-year?
- Dianthus Therapeutics's R&D increased by 27.9% year-over-year, from $27M to $34.53M.
- What is the long-term trend for Dianthus Therapeutics's R&D?
- Over 3 years (2021 to 2024), Dianthus Therapeutics's R&D has grown at a 23.4% compound annual growth rate (CAGR), from $46.77M to $87.9M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Dianthus Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude